Month: April 2022

Context Therapeutics® Announces Encouraging Preclinical Data from Two Programs to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2022

Written by Customer Service on April 11, 2022. Posted in Public Companies.

Lead clinical-stage oral progesterone receptor (PR) antagonist ONA-XR demonstrates strong efficacy across multiple PR+ solid tumor models First presentation of preclinical CLDN6xCD3 bispecific antibody optimization, binding properties, and T-cell dependent cytotoxicity Context to host webinar with AACR presenters on Wednesday, April 13, 2022, at 11 a.m. ET PHILADELPHIA, April 11, 2022 (GLOBE NEWSWIRE) — Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company developing small molecule and immunotherapy treatments for breast and gynecological cancers, today announced encouraging preclinical data from two pipeline programs, including in vivo combination and immunomodulation data evaluating onapristone extended release (ONA-XR), the company’s lead clinical program. The data are being presented...

Canacol Energy’s Pola 1 Exploration Well Targeting 470 BCF of Gross Mean Risked Conventional Gas Resource in Q3 2022

Written by Customer Service on April 11, 2022. Posted in Public Companies.

CALGARY, Alberta, April 11, 2022 (GLOBE NEWSWIRE) — Canacol Energy Ltd. (“Canacol” or the “Corporation”) (TSX: CNE; OTCQX: CNNEF; BVC: ‎CNEC) is pleased to report on the conventional natural gas prospective resources (resources other than reserves) ‎for its Pola-1 prospect on the VMM-45 exploration block located in the Middle Magdalena Valley (“MMV”) basin of Colombia (the “Audited Area”). Boury Global Energy Consultants Ltd. (“BGEC”), Canacol’s independent qualified resources auditor, ‎was ‎commissioned ‎to conduct an independent prospective resources audit of Canacol’s internal ‎estimates of prospective ‎resources for ‎the Audited Area effective December 31, 2021‎ (the “BGEC ‎Report”). ‎ Canacol is a natural gas focused exploration and production ‎company, and the largest independent gas producer in Colombia.‎ VMM-45 is one of...

CTO Realty Growth Announces $30.0 Million Preferred Investment in Watters Creek at Montgomery Farm in the Allen Submarket of Dallas, TX

Written by Customer Service on April 11, 2022. Posted in Public Companies.

WINTER PARK, Fla., April 11, 2022 (GLOBE NEWSWIRE) — CTO Realty Growth, Inc. (NYSE: CTO) (the “Company” or “CTO”) today announced it has entered into a preferred equity agreement to provide $30.0 million of funding towards the acquisition of the Watters Creek at Montgomery Farm grocery-anchored, mixed-use property in Allen, Texas (the “Preferred Investment”). Watters Creek at Montgomery Farm is approximately 458,000 square feet of grocery-anchored retail and office, anchored by Market Street, Anthropologie, Mi Cocina, DSW, The Cheesecake Factory, Brio Italian Grille, and Michaels, and includes a variety of national and local retailers and restaurants (the “Watters Creek Property” or “Property”). “As we’ve seen cap rates for well-located retail and mixed-use assets compress over the past twelve months, we’re selectively making structured...

Solaris Reports 616m of 0.6% CuEq in Additional Drilling at Warintza East, Establishes Continuity of Mineralization with Warintza Central

Written by Customer Service on April 11, 2022. Posted in Public Companies.

VANCOUVER, British Columbia, April 11, 2022 (GLOBE NEWSWIRE) — Solaris Resources Inc. (TSX: SLS; OTCQB: SLSSF) (“Solaris” or “the Company”) is pleased to report assay results from a series of additional holes from mineral resource growth drilling at its Warintza Project (“Warintza” or “the Project”) in southeastern Ecuador. Highlights are listed below, with detailed results in Tables 1-2. Key Takeaways Since the discovery of Warintza East in mid-2021, approximately 1km east of Warintza Central, limited drilling has been completed on the open area between the two deposits that would fall into the eastern sector of the conceptual pit design for Warintza Central as uncategorized waste – these results now establish continuity of mineralization between the two deposits with Warintza East remaining entirely open and undrilled to the...

Eton Pharmaceuticals Announces FDA Approval of Cysteine Hydrochloride Injection

Written by Customer Service on April 11, 2022. Posted in Public Companies.

DEER PARK, Ill., April 11, 2022 (GLOBE NEWSWIRE) — Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it has received final approval from the U.S. Food and Drug Administration (FDA) for its cysteine hydrochloride abbreviated new drug application (ANDA), a bioequivalent generic of Exela Pharma Sciences’ Elcys™. Eton was granted 180 days of generic exclusivity as a result of being the first ANDA submitted against the reference product. The 180-day exclusivity period will begin upon Eton’s commercialization of the product. “We are pleased to see another one of our products receive FDA approval. Despite Exela’s attempts to monopolize a decades old treatment with patents that we believe to be frivolous, we are eager...

Magnetic North Acquisition Corp. Announces Non-Brokered Private Placement of Up to $1 Million

Written by Customer Service on April 11, 2022. Posted in Public Companies.

**Not for distribution to United States Newswire Services or release publication, distribution or dissemination, directly or indirectly, in the United States. Any failure to comply with this restriction may constitute a violation of U.S. Securities Laws** CALGARY, Alberta and TORONTO, April 11, 2022 (GLOBE NEWSWIRE) — Magnetic North Acquisition Corp. (TSXV: MNC) (“Magnetic North” or the “Company”) is pleased to announce a planned non-brokered private placement (the “Financing”) for gross proceeds of up to approximately $1,000,008.00 CAD. The Financing consists of up to 105,264 Units at $9.50 per Unit. Each Unit is comprised of one Series A Preferred Share ‎(“Series A Preferred Shares‎”) and one Series A Preferred Share purchase warrant (“Warrant”) for gross proceeds of up to $1,000,008.00 CAD. Each Warrant will entitle the holder...

Dundee Precious Announces First Quarter 2022 Preliminary Production Results

Written by Customer Service on April 11, 2022. Posted in Public Companies.

TORONTO, April 11, 2022 (GLOBE NEWSWIRE) — Dundee Precious Metals Inc. (TSX: DPM) (“DPM” or “the Company”) announced preliminary production results from both of its mines and smelter for the three months ended March 31, 2022. The Company confirmed that all operations are on track to meet previously issued guidance for 2022. “The first quarter was a solid start to the year, with production at Chelopech and Ada Tepe in-line with guidance,” said David Rae, President and Chief Executive Officer. “At the end of March, we also announced an optimized life of mine plan for Chelopech, which resulted in higher gold and copper production, and an extended mine life to 2030.” Production Highlights Preliminary results for the first quarter are provided in the table below: Ore processed Metals contained in concentrate produced Payable metals...

Purple Biotech Presents Positive Interim Phase 1b Study Results for CM24 at the American Association of Cancer Research 2022 Annual Meeting

Written by Customer Service on April 11, 2022. Posted in Public Companies.

First-in-class monoclonal antibody in combination with Opdivo® (nivolumab) demonstrates strong safety and an initial efficacy profile for PDAC REHOVOT, Israel, April 11, 2022 (GLOBE NEWSWIRE) — Purple Biotech Ltd. (“Purple Biotech”, or the “Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies by overcoming tumor immune evasion and drug resistance today announced favorable safety and efficacy data supporting the advancement of CM24, a first-in-class clinical stage monoclonal antibody with the potential to treat multiple solid tumor cancers. Data from the Phase 1b study of CM24 in combination with Opdivo® (nivolumab) is being presented in a poster entitled “Interim Safety and Efficacy Results from a Phase 1b Study of CM24 in Combination with Nivolumab...

Fluence Announces Agreement to Acquire AI-Enabled Software-as-a-Service Company Nispera

Written by Customer Service on April 11, 2022. Posted in Mergers And Acquisitions.

In increasingly sophisticated energy markets, forecast of granular asset availability, production profile, and management becomes imperative for value capture Enhances Fluence’s digital leadership position with a combined digital portfolio of 15 GW contracted or under management Accelerates development and roll-out of new applications on Fluence IQ Digital Platform Strengthens foundation for recurring revenue and expected to be EBITDA accretive by 2024ARLINGTON, Va., April 11, 2022 (GLOBE NEWSWIRE) — Fluence (NASDAQ: FLNC), a leading global provider of energy storage products, services and digital applications for renewables and storage, announced today that it has entered into an agreement to acquire Nispera AG (Nispera). Nispera is a Zurich-based provider of artificial intelligence (AI) and machine learning-enabled software-as-a-service...

Diffusion Pharmaceuticals Completes Dosing in Altitude Trial

Written by Customer Service on April 11, 2022. Posted in Public Companies.

Topline data expected within two months Blinded, interim data to be presented at the Undersea & Hyperbaric Medical Society’s Annual Scientific Meeting in May 2022 CHARLOTTESVILLE, Va., April 11, 2022 (GLOBE NEWSWIRE) — Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that enhance the body’s ability to deliver oxygen to areas where it is needed most, today announced the final participant has completed dosing in its Altitude Trial. The Altitude Trial is a double-blind, randomized, placebo-controlled crossover study, designed to evaluate the effects of TSC on maximal oxygen consumption, or VO2, and partial pressure of arterial blood oxygen, or PaO2, in normal healthy volunteers subjected to incremental levels of physical exertion while exposed...

Month: April 2022

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals